Adlai Nortye (NASDAQ:ANL) Receives Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Adlai Nortye (NASDAQ:ANL) in a research note issued to investors on Monday,Benzinga reports. The brokerage currently has a $9.00 price objective on the stock.

Adlai Nortye Trading Up 6.3 %

Shares of ANL stock opened at $3.02 on Monday. The stock has a 50 day moving average price of $2.15 and a two-hundred day moving average price of $4.61. Adlai Nortye has a fifty-two week low of $1.85 and a fifty-two week high of $17.48.

Adlai Nortye Company Profile

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.